Table 2.
Comparison of neoadjuvant chemoradiotherapy plus surgery versus surgery alone
| Clinical study | Patients, n | Histology | Stadium | RT dose | Chemotherapy | Follow-up, months | Treatment | Median survival, months | 3-year survival, % | p-value |
|---|---|---|---|---|---|---|---|---|---|---|
| Nygaard et al., 1983/1988 | 88 | SCC | T1–2 | 35 Gy | cisplatin | 18 | CRT+S | NA | 17 | ns |
| N0–1 | 1.75 Gy/fraction, 4 weeks | bleomycin, 2 cycles sequentially | S | NA | 9 | |||||
| M0 | ||||||||||
| Le Prise et al., 1988/1991 | 86 | SCC | T1–3 | 20 Gy | cisplatin | 12 | CRT+S | 10 | 19 | ns |
| N0 | 2 Gy/fraction, 12 days | 5-FU, 2 cycles sequentially | S | 10 | 14 | |||||
| M0 | ||||||||||
| Apinop et al., 1986/1992 | 69 | SCC | – | 40 Gy | cisplatin | 12 | CRT+S | 10 | 26 | ns |
| 2 Gy/fraction, 4 weeks | 5-FU, 2 cycles concurrently | S | 7 | 20 | ||||||
| Bosset et al., 1989/1995 | 282 | SCC | T1–3 | 37 Gy | cisplatin, | 55 | CRT+S | 19 | 39 | ns |
| N0–1 | 3.7 Gy/fraction, 2 weeks | 2 cycles sequentially | S | 19 | 37 | |||||
| M0 | ||||||||||
| Urba et al., 1989/1994 | 100 | SCC | T1–3 | 45 Gy | cisplatin | 98 | CRT+S | 17 | 30 | 0.15 |
| Adeno | N0–1 | 1.5 Gy/fraction, 3 weeks | vinblastine 5-FU, 2 cycles concurrently | S | 18 | 16 | ||||
| M0 | ||||||||||
| Walsh, 1990/1995 | 61 | SCC | T1–3 | 40 Gy | cisplatin | 10 | CRT+S | 16 | 32 | <0.01 |
| N0–1 | 2.7 Gy/fraction, 3 weeks | 5-FU, 2 cycles concurrently | S | 11 | 6 | |||||
| M0 | ||||||||||
| Cao et al., 1991/2000a | 236 | SCC | T1–4 | 40 Gy | cisplatin | 60 | CRT+S | NA | 73.3a | <0.005 |
| N0–1 | 2 Gy/fraction, 4 weeks | 5-FU mitomycin C, 2 cycles concurrently | S | NA | 53.4a | |||||
| M0 | ||||||||||
| Burmeister et al., 1994/2000 | 256 | SCC | T1–3 | 35 Gy | cisplatin | 65 | CRT+S | 19 | NA | 0.38 |
| Adeno | N0–1 | 2.3 Gy/fraction, 3 weeks | 5-FU, concurrently | S | 22 | NA | ||||
| M0 | ||||||||||
| Lee et al., 1993/1996 | 101 | SCC | T1–3 | 45.6 Gy | cisplatin | 25 | CRT+S | 28.2 | NA | 0.69 |
| N0–1 | 1.2 Gy/fraction, 28 days | 5-FU, concurrently | S | 27.3 | NA | |||||
| M0 | ||||||||||
| Tepper et al., 1997/2000 | 56 | SCC | T1–3 | 50.4 Gy | cisplatin | 60 | CRT+S | 54 | NA | 0.002 |
| Adeno | N0–1 | 1.8 Gy/fraction, 5–6 weeks | 5-FU, 2 cycles concurrently | S | 21 | NA | ||||
| M0 | ||||||||||
| Natsugoe et al., 1997/2001a | 45 | SCC | T2–3 | 40 Gy | cisplatin | 24 | CRT+S | NA | 57 | 0.58 |
| N0–1 | 2 Gy/fraction, 4 weeks | 5-FU | S | NA | 41 | |||||
| M0–1 | ||||||||||
a
Survival measured in percentage (%) instead of months.
Adeno = Adenocarcinoma; SCC = squamous cell carcinoma; 5-FU = 5-fluorouracil; CRT+S = chemoradiotherapy plus surgery; S = surgery; NA = not available.